Keybank National Association OH Decreases Position in Celgene Co. (NASDAQ:CELG)

Keybank National Association OH lessened its holdings in Celgene Co. (NASDAQ:CELG) by 7.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 192,009 shares of the biopharmaceutical company’s stock after selling 15,588 shares during the quarter. Keybank National Association OH’s holdings in Celgene were worth $19,067,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of CELG. First PREMIER Bank purchased a new position in Celgene in the 3rd quarter worth $26,000. Liberty Wealth Management LLC raised its position in Celgene by 212.8% in the 2nd quarter. Liberty Wealth Management LLC now owns 294 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 200 shares during the period. B & T Capital Management DBA Alpha Capital Management purchased a new position in Celgene in the 3rd quarter worth $28,000. Massey Quick Simon & CO. LLC purchased a new position in Celgene in the 2nd quarter worth $33,000. Finally, Lenox Wealth Advisors LLC purchased a new position in Celgene in the 3rd quarter worth $37,000. Institutional investors own 72.31% of the company’s stock.

In related news, insider Terrie Curran sold 11,338 shares of the business’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $98.27, for a total transaction of $1,114,185.26. Following the sale, the insider now owns 13,493 shares of the company’s stock, valued at $1,325,957.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.39% of the company’s stock.

Shares of CELG traded up $0.44 during trading hours on Friday, reaching $109.44. 313,065 shares of the company traded hands, compared to its average volume of 3,870,767. The company’s fifty day moving average price is $102.33 and its two-hundred day moving average price is $96.68. The company has a market capitalization of $76.64 billion, a price-to-earnings ratio of 14.38, a price-to-earnings-growth ratio of 0.51 and a beta of 1.41. The company has a quick ratio of 2.80, a current ratio of 2.89 and a debt-to-equity ratio of 1.51. Celgene Co. has a 12 month low of $58.59 and a 12 month high of $109.07.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $2.99 EPS for the quarter, topping the consensus estimate of $2.70 by $0.29. Celgene had a net margin of 34.63% and a return on equity of 78.15%. The business had revenue of $4.52 billion for the quarter, compared to analyst estimates of $4.39 billion. During the same quarter in the previous year, the firm posted $2.29 earnings per share. Celgene’s quarterly revenue was up 16.1% on a year-over-year basis. On average, analysts expect that Celgene Co. will post 10.7 EPS for the current year.

A number of equities analysts recently commented on the stock. BidaskClub upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Robert W. Baird cut shares of Celgene from an “outperform” rating to a “neutral” rating and set a $101.00 price objective on the stock. in a research report on Friday, November 1st. Zacks Investment Research upgraded shares of Celgene from a “sell” rating to a “hold” rating and set a $94.00 price objective on the stock in a research report on Tuesday, July 23rd. Wells Fargo & Co set a $110.00 price objective on shares of Celgene and gave the company a “hold” rating in a research report on Friday, November 1st. Finally, ValuEngine cut shares of Celgene from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, nineteen have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $97.31.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

See Also: Put Option

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply